Vasomotor symptoms, the so-called hot flashes with or without sweats, affect many women at peri-menopausal age and sometimes may persist in the long term with relevant consequences on the sleep pattern and occupational activities. The mechanisms are not well clear, but they certainly include some hyper-reactivity of the term-regulation centre within the central nervous system (CNS) that reacts excessively to standard stimuli for temperature adjustments.
The concerned effector is an excitatory neurotransmitter called glutamate. It increases at menopausal age due to the fall of steroid hormones and peaks during the hormonal fluctuations typical of early menopause. Also, CNS homocysteine contributes by directly stimulating glutamate receptors and by inhibiting its re-adsorption at synaptic space, thus amplifying glutamate effect.
Impryl, due to its content in methylfolate and methylcobalamin, that can enter the CNS, favours the decrease of glutamate by inducing its consumption for the synthesis of glutathione and by activating the removal of homocysteine within the CNS. Treated women reported a very fast relief from symptoms, already after three days of treatment, and almost all of them were symptom-free after one week.
Besides, circulating homocysteine is also an independent risk factor for osteoporosis. It is known that even the plain folic acid can improve bone density and reduce pathological fractures. Impryl, thanks to the all-round support to the folate pathway and its suitability also to the carriers of the common genetic variants of the enzymes, qualifies as the better comprehensive menopausal support so far available with relevant activity on both the symptoms and the complications.